Banque Cantonale Vaudoise Sells 6,856 Shares of AC Immune SA (NASDAQ:ACIU)

Banque Cantonale Vaudoise lessened its stake in AC Immune SA (NASDAQ:ACIU) by 27.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,562 shares of the company’s stock after selling 6,856 shares during the quarter. Banque Cantonale Vaudoise’s holdings in AC Immune were worth $70,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Assenagon Asset Management S.A. increased its holdings in shares of AC Immune by 294.7% in the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after purchasing an additional 328,312 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in AC Immune by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock worth $2,602,000 after buying an additional 136,300 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in AC Immune in the 2nd quarter valued at $218,000. Vanguard Capital Wealth Advisors acquired a new stake in shares of AC Immune in the 2nd quarter valued at $56,000. Finally, Lazard Asset Management LLC bought a new stake in shares of AC Immune during the first quarter worth $30,000. 51.36% of the stock is owned by institutional investors.

AC Immune Stock Up 2.7 %

ACIU stock opened at $3.38 on Friday. AC Immune SA has a twelve month low of $2.25 and a twelve month high of $5.14. The company has a market cap of $334.42 million, a P/E ratio of -7.35 and a beta of 1.28. The business’s fifty day moving average is $3.30 and its 200-day moving average is $3.51.

Wall Street Analyst Weigh In

ACIU has been the topic of several recent research reports. StockNews.com cut AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of AC Immune in a research note on Friday, November 15th.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.